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Summary
BACKGROUND: There is considerable heterogeneity in
the use of chemotherapy in early breast cancer (BC), des-
pite international recommendations issued from the
NCCN, NIH and the St.Gallen bi-annual conference.
METHODS: We included 1,535 patients from seven Swiss
cancer registries between 2003 and 2005 receiving chemo-
therapy for stage I to III BC. Chemotherapy was categor-
ised into (a) FAC/FEC, anthracyclines followed by CMF or
anthracycline-taxane combinations (FAC-T) (781 patients)
and (b) other chemotherapy regimens such as CMF/AC
(EC) (754 patients). Predictors for choosing FAC-T over
non-FAC-T chemotherapy were separately determined in
all patients and in ER-negative patients (n = 496) by mul-
tivariate logistic regression analysis.
RESULTS: The use of FAC-T increased significantly over
time, from 44% in 2003 to 55% in 2005. BC stage III
(versus stage I-II) and nodal positivity were the predomin-
ant predictors for using FAC-T chemotherapy in the adjus-
ted model (odds ratio (OR) 4.1, 95%-confidence intervals
(CI) 2.6–6.3 and OR 3.0, 95%-CI 2.0–4.4, respectively). In
high-risk ER-negative BC patients, poor histological dif-
ferentiation was more important to choose FAC-T chemo-
therapy (OR 3.8, 95%-CI 1.9–7.5) than tumour stage or
nodal status. The use of FAC-T chemotherapy varied sub-
stantially among the seven geographic regions, from 20%
in rural Grisons-Glarus to 73% in Zurich.
CONCLUSIONS: Tumour biology is a predominant factor
for choosing FAC-T over older chemotherapy regimens
in patients with ER-negative early BC, but improvements
should be made to reduce the substantial regional hetero-
geneity. Further epidemiological studies should assess how
the use of FAC-T chemotherapy is affecting clinical out-
come in patients with early BC and different risk profiles.
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Introduction
Combination chemotherapy is indicated in non minimal-
risk early breast cancer (BC), as there is a relevant reduc-
tion of the risk of recurrence that can be achieved with
an acceptable level of treatment-related adverse events [1].
Over time, three generations of chemotherapy regimens
have been evaluated, which are the cyclophosphamide, me-
thotrexate, and 5-fluorouracil (CMF) regimen [2], the
anthracycline-based regimens [3–9], and the taxane-con-
taining regimens [10–15]. According to the 2005 Oxford
meta-analysis, adjuvant treatment with six months of ad-
juvant anthracycline-based chemotherapy reduces the an-
nual BC mortality by about 38% for women younger than
50 years of age, and by about 20% for those aged 50–69
years [16]. One of the persisting controversies in the ad-
juvant treatment of early BC is the type of chemotherapy
chosen for patients with oestrogen receptor (ER) negative
early BC. Following the first publication in 2003 [11],
accumulating data support the use of 5-fluorouracil/dox-
orubicin(epirubicin)/cyclophosphamide (FAC/FEC) and
anthracycline-taxane containing chemotherapy in patients
with ER-negative BC, resulting in improved clinical out-
come compared to CMF or AC/EC chemotherapy regimens
[11–15, 17–20]. This is also supported by more recent
data from the Early Breast Cancer Trialists’ Collaborative
Group (EBCTCG), indicating that by the addition of tax-
anes to antracycline-containing regimens, recurrence-free
survival is improved in patients with ER-negative BC [21].
However, it is unclear how these data should be applied to
the individual patient. Several treatment guidelines, includ-
ing the St. Gallen consensus recommendations [22], the
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National Comprehensive Cancer Network (NCCN) Breast
Cancer guidelines [23–24] and the National Institutes of
Health (NIH) consensus recommendations [25], have been
developed to help physicians to choose between the differ-
ent chemotherapy regimens, based upon patient and tumour
characteristics. The aim of the present study is to assess
the patterns of use of different chemotherapy regimens, and
more specifically assess the introduction of the more recent
FAC/FEC and anthracycline-taxane containing chemother-
apy in patients with ER-negative early BC.
Methods
Study population and data collection
For this study, we used data from a representative sample
of 4820 women who had being diagnosed with invasive BC
between January 1st, 2003 and December 31st, 2005. Pa-
tients were identified from seven population-based cancer
registries covering roughly 3.5 Mio inhabitants, or 47% of
the Swiss population (fig. 1). At the time of the study ini-
tiation, some regions in Switzerland were not covered by a
cancer registry, but there was no indication that this intro-
duced any bias to the data. Routine indicators of data com-
pleteness and quality of the participating registries were
good, and patients identified on the basis of death certific-
ates only were excluded from the study. The proportion of
histological verification was over 90% [26]. A more de-
tailed methodology of this study has been reported previ-
ously [27–28]. Based on the requirements of the European
Society of Mastology (EUSOMA) Audit system on Quality
of Breast Cancer Treatment criteria [29], a database was
designed for data entry at the site of the cancer registries.
Items included information on patient and tumour charac-
teristics, diagnostic circumstances and treatments planed
and delivered. Trained registry staff were centrally instruc-
ted and following this data items were abstracted from
pathology reports, medical charts and questionnaires sent
Figure 1
Consort diagram.
* calculated from the breast cancer yearly average incidence rates
in the periods 1999–2003 and 2004–2008 (http://www.nicer.org/
Editor/files/ cancer_incidence.pdf)
BC = breast cancer, NSCT = nonstandard chemotherapy regimens.
to treating physicians, and added to the database by trained
staff. Registries could choose between collecting inform-
ation on all registered and eligible cases diagnosed with
BC between 2003 and 2005, or on a random sample of
at least 500 cases. Five registries (Geneva, Valais, Ticino,
St. Gallen-Appenzell, Grisons Glarus) collected informa-
tion on all registered cases, and the registries from Basel
and Zurich collected information on a random sample of
505 cases, using the methodology as described previously
[30]. Tests of representativeness did not suggest any bias
regarding patient age, BC stage and biology. Breast cancer
staging used the 6th edition of the American Joint Commit-
tee on Cancer staging criteria [31]. From the final dataset,
we included 1,535 patients ≤75 years of age with incident
BC stage I-III, receiving either adjuvant (1,317 cases, 86%)
or neo-adjuvant (218 cases, 14%) chemotherapy in a cur-
ative intention (fig. 1). There were 121 patients who were
intended to receive chemotherapy, but in whom chemother-
apy was never started, mostly due to patient refusal. These
patients were defined as not having received chemotherapy.
The study was accepted by the Cantonal Ethics Committee
in St. Gallen, where the study centre is located.
Data analysis
Chemotherapy regimens were grouped into two categories
as follows: (a) FAC/FEC for ≥6 cycles, anthracyclines fol-
lowed by CMF or anthracycline-taxane combinations
(FAC-T) (781 patients) and (b) other chemotherapy regi-
mens such as CMF for 6 cycles, AC(EC) for 4 cycles
or other regimens, including non-standard chemotherapy
(non-FAC-T) (754 patients). Non-standard chemotherapy
(NSCT) was defined as drugs or drug combinations that
were not registered or not investigated for adjuvant use,
or proved to be inferior when tested against standard re-
gimens. The use of FAC-T and non-FAC-T chemotherapy
was assessed over the years of BC diagnosis (2003 to
2004), using Wilcoxon-type tests for trend. Patient and
tumour characteristics, socio-economic and health care
provider-related factors were compared between patients
receiving FAC-T chemotherapy versus those receiving
non-FAC-T chemotherapy using two-sided Fisher’s exact
test. Predictors for choosing FAC-T over non-FAC-T
chemotherapy were separately determined in all patients
receiving chemotherapy and in ER-negative patients (n =
496) using multivariate logistic regression analysis, adjust-
ing for known prognostic factors such as tumour stage and
biology. For the analysis of potential predictors for chemo-
therapy, women receiving FAC-T were defined as cases
and women not receiving FAC-T as controls. Predictors
for the use of NSCT were similarly assessed. The follow-
ing parameters were assessed as potential predictors within
multivariate regression analysis: HER2-status [a result of
immuno-histochemical analysis of 3+ (IHC 3+), or a pos-
itive result on fluorescence in situ hybridisation (FISH) for
HER2 gene amplification, histopathological grading (poor
versus good/intermediate), tumour stage (stage I/II versus
III), nodal status (nodal negative versus nodal positive),
lymphovascular invasion (positive lymphovascular inva-
sion versus no invasion), patient age (≤50 versus >50
years), affluence (highest quartile of median income versus
others), type of health care insurance (private versus other),
Original article Swiss Med Wkly. 2012;142:w13571
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education (high school degree versus other) as derived
from the type of occupation, breast surgeon’s annual yearly
caseload (highest tertile versus others, with the highest ter-
tile corresponding to ≥27 breast surgeries per year), case
presentation at the local multidisciplinary tumour confer-
ence (MDTC), treatment within an institute participating
in clinical research, and patient residence (urban/suburban
versus rural residence, as defined by the National Bureau
of Statistics [32]). The definition for HER2- and ER-status
was identical in patients from all regions. Data for the type
of health care insurance (HCI) were available for 84% of
the patients, education for 74%, yearly surgical caseload
for 72% and MDTC for 83% of the patients. The geograph-
ic heterogeneity of using FAC-T or Non-FAC-T chemo-
therapy was assessed across the regions of patient residen-
ce (according to the 7 recruiting cancer registries), using
Fisher’s exact test. Finally, adherence to the full number of
chemotherapy cycles (FAC-T or Non-FAC-T) was assessed
using chi-square statistics. All tests of significance were
two-sided, and p <0.05 was considered significant. With
multivariate logistic regression analysis, introducing mul-
tiple prognostic factors such as tumour stage and biology,
a p-value of 0.01 was considered significant. All statist-
ical analyses were performed using STATA 11.0 software
(STATA Corp, College Station, Texas, U.S.).
Results
Study population and chemotherapy regimens
FAC/FEC chemotherapy for ≥6 cycles was the most fre-
quently used treatment schedule in 548 patients (36%), fol-
lowed by 4 cycles of AC/EC in 481 patients (31%). FAC-T
chemotherapy was given in 781 patients (51%, non-FAC-
T in 754 patients (49%). The use of FAC-T chemother-
apy increased significantly over time, from 44% in 2003
to 55% in 2005 (p = 0.002 for trend). NSCT was given
in 105 patients (7%), including regimens such as leuker-
an/methotrexate/5-FU (LMF) in 21 cases, epirubicin/car-
boplatin/5-fluorouracil in 5 cases, navelbine in 14 cases,
Figure 2
Forrest plot for the use of FAC-T chemotherapy compared to non-
FAC-T chemotherapy in the overall study group (ER-positive and
ER-negative early breast cancer). Clinical significance (p <0.01)
from adjusted multivariate analysis is marked by an asterisk. OR =
odds ratio, ER = oestrogen receptor, BC = breast cancer, MDTC =
multidisciplinary tumour conference.
paraplatin and paclitaxel in 8 cases, capecitabine ± navel-
bine in 7 cases, single-agent epirubicin or liposomal doxor-
ubicin in 8 cases, carboplatin/gemcitabine in 3 cases. The
use of NSCT did not significantly change over time (5%
in 2003 and 8% in 2005). Patient and tumour character-
istics were significantly different between patients receiv-
ing FAC-T chemotherapy and those receiving non-FAC-T,
with patients receiving FAC-T having a poorer risk pro-
file (table 1). Patients who were treated in an institution
participating in clinical research and living in an urban/
suburban region were significantly more likely to receive
FAC-T chemotherapy. FAC-T chemotherapy was more of-
ten used in the neo-adjuvant setting compared to non-FAC-
T chemotherapy (19 vs. 9%, p <0.001). Overall, 496 out
of the 1535 patients had ER-negative BC (32%), and 1026
patients had node-positive BC (67%). Within the major
patient subgroups, FAC-T chemotherapy was most often
given to patients ≤50 years of age with node-positive, ER-
negative BC (81%) and least often to patients with well or
moderately differentiated, ER-positive BC (22%) (table 2).
Predictors of FAC-T and non-FAC-T chemotherapy
In all patients, tumour stage, biology and patient age were
significant predictors for choosing FAC-T chemotherapy
over non-FAC-T chemotherapy (fig. 2). In the adjusted
multivariate model, BC stage III (versus stage I–II) and
nodal positivity were the predominant predictors for using
FAC-T chemotherapy (odds ratio (OR) 4.1, 95%-confiden-
ce intervals (CI) 2.6–6.3 and OR 3.0, 95%-CI 2.0–4.4, re-
spectively). Patients with a rural residence were less likely
to receive FAC-T compared to non-FAC-T chemotherapy
(adjusted OR 0.4, 95%-CI 0.3–0.6). In high-risk ER-negat-
ive BC patients, poor histological differentiation was more
important to choose FAC-T chemotherapy over non-FAC-
T chemotherapy (adjusted OR 3.8, 95%-CI 1.9–7.5) than
was tumour stage or nodal status (fig. 3). In ER-negative
BC patients, tumour stage (adjusted OR 2.6, 95%-CI
0.9–6.8) and HER2-status (adjusted OR 1.8, 95%-CI
0.9–3.8) were no more significant as predictors for choos-
ing FAC-T chemotherapy over non-FAC-T chemotherapy.
Figure 3
Forrest plot for the use of FAC-T chemotherapy compared to non-
FAC-T chemotherapy in patients with ER-negative early breast
cancer. Clinical significance (p <0.01) from adjusted multivariate
analysis is marked by an asterisk. OR = odds ratio, BC = breast
cancer, MDTC = multidisciplinary tumour conference.
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Patients being treated by a breast surgeon with a high an-
nual caseload were more likely to receive FAC-T chemo-
therapy compared to non-FAC-T chemotherapy (adjusted
OR 4.2, 95%-CI 1.5–11.6). The use of FAC-T chemother-
apy varied substantially among the seven geographic re-
gions and ranged from 20% in rural Grisons-Glarus to 73%
in urban Zurich. In the adjusted multivariate model, pa-
tients with residence in the regions of Geneva (OR 2.5,
95%-CI 1.9–3.3), Zurich (OR 3.9, 95%-CI 2.5–6.0) and
St.Gallen-Appenzell (OR 1.6, 95%-CI 1.2–2.2) were sig-
nificantly more likely to receive FAC-T compared to non-
FAC-T chemotherapy. On the contrary, patients with res-
idence in the regions of Ticino (OR 0.2, 95%-CI 0.2–0.3)
and Grisons-Glarus (OR 0.2, 95%-CI 0.1–0.3) were less
likely to receive FAC-T compared to non-FAC-T chemo-
therapy. In patients with ER-negative BC, the use of FAC-T
chemotherapy ranged from 32% in Grisons-Glarus to 77%
in urban French-speaking Geneva. In the adjusted model
in ER-negative BC, patients with residence in the regions
of Geneva (OR 3.5, 95%-CI 1.9–6.4), St.Gallen-Appenzell
(OR 3.1, 95%-CI 1.7–5.4) were significantly more likely
to receive FAC-T compared to non-FAC-T chemotherapy.
On the contrary, patients with residence in the regions of
Ticino (OR 0.2, 95%-CI 0.1–0.4) and Grisons-Glarus (OR
0.2, 95%-CI 0.1–0.5) were less likely to receive FAC-T
compared to non-FAC-T chemotherapy.
Table 1: Patient and tumour characteristics according to chemotherapy intensity in all patients receiving chemotherapy.
FAC-T (n = 781) Non-FAC-T (n = 754) p-value
Patients (%) Patients (%) (χ2-Test)
ER-status <0.001
Positive 477 (61) 556 (74)
Negative 300 (39) 196 (26)
HER2-status 0.001
Negative 487 (71) 513 (79)
Positive 202 (29) 138 (21)
Histological grading <0.001
1–2 374 (49) 479 (65)
3 382 (51) 260 (35)
Stage <0.001
I–II 459 (59) 616 (82)
III 322 (41) 138 (18)
Nodal status <0.001
Positive 598 (77) 428 (57)
Negative 183 (23) 326 (43)
Lymphovascular invasion 0.23
Negative 96 (13) 78 (10)
Positive 669 (87) 669 (90)
Patient age [Median (SD)] 51.1 54.4 <0.001a
<50 years 371 (48) 276 (37)
≥50 years 410 (52) 478 (63)
Surgical case-load <0.001
Low 386 (62) 356 (74)
High 241 (38) 128 (26)
Health care insurance 0.06
Basic 451 (64) 399 (69)
Private 259 (36) 182 (31)
Income category 0.03
Low 616 (79) 628 (83)
High 165 (21) 126 (17)
Education 0.80
Basic 536 (85) 429 (86)
Tertiary 94 (15) 71 (14)
MDTC 0.54
No 339 (48) 285 (50)
Yes 362 (52) 283 (50)
Clinical research <0.001
No 401 (51) 458 (61)
Yes 380 (49) 296 (39)
Residence <0.001
Rural 136 (17) 189 (25)
Urban 645 (83) 565 (75)
N = number of patients, SD = standard deviation, HICT = high-intensity chemotherapy, LICHT = low-intensity chemotherapy, ER = oestrogen receptor status, MDTC =
multidisciplinary tumour conference.
a p-value (T-test)
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Treatment adherence
In patients with both ER-positive or ER-negative BC, few-
er patients in the FAC-T chemotherapy group were able to
receive the full number of planned treatment cycles com-
pared to patients in the non-FAC-T chemotherapy group
(83% vs. 92%, p <0.001). Similarly, fewer patients in the
FAC-T chemotherapy group were able to receive the full
number of planned treatment cycles compared to patients
in the non-FAC-T chemotherapy group in patients with ER-
negative BC (81% vs. 94%, p <0.001). This was mainly
due to a high proportion of patients receiving all 4 cycles
of AC/EC chemotherapy (97% of patients in both the over-
all study group and in patients with ER-negative BC). In
the adjusted multivariate model, affiliation to the non-FAC-
T chemotherapy group was the significant predictor for the
adherence to the full number of chemotherapy cycles in
the overall study population (OR 2.58, 95%-CI 1.39–4.79)
and in patients with ER-negative BC (OR 4.9, 95%-CI
1.5–16.3). Patient and tumour characteristics, socioeco-
nomic and health care provider-related factors did not pre-
dict for the adherence to the full number of chemotherapy
cycles. In particular, there was no evidence for elderly pa-
tients to have increased toxicity or inferior treatment adher-
ence compared to younger patients.
Discussion
In the present population-based study, the patterns of use
of different chemotherapy regimens in early BC were ana-
lysed, and tumour biology was found to be of increasing
predictive significance for choosing FAC-T chemotherapy
over non-FAC-T chemotherapy in patients with high-risk
ER-negative BC. Chemotherapy regimens such as CMF
[2] or AC/EC [4] are typically used in patients with node-
negative early BC, while the newer regimens such as AC/
EC followed by CMF [33], Canadian CEF [6–8], the CAF
regimen [5], dose-dense cyclophosphamide, doxorubicin
and paclitaxel [11–12, 15], FEC100 followed by docetaxel
[14], tailored FEC [34], FEC100 [35] and TAC (docetaxel,
doxorubicin, cyclophosphamide) [13] are more frequently
offered to patients with node-positive BC. In our study,
72% of patients with ER-negative, node-positive BC re-
ceived FAC-T chemotherapy. In 2006, Berry and col-
leagues retrospectively assessed the improvements in ad-
juvant chemotherapy in patients with ER-negative, node-
positive BC compared to patients with ER-positive BC re-
ceiving adjuvant tamoxifen [36]. They compared disease-
free and overall survival according to ER-status among
patients enrolled in three consecutive randomised trials of
chemotherapy, and found a 55% improvement of overall
survival in patients with ER-negative disease receiving bi-
weekly AC plus paclitaxel [34], compared to low-dose
CAF [37]. These data suggest that the choice of chemother-
apy regimens has a clinically relevant effect on the clinic-
al outcome in patients with ER-negative BC. At the time
of BC diagnosis (between 2003 and 2005), data support-
ing the use of more than 4 cycles of AC/EC chemotherapy
[3, 38], or the addition of taxanes to anthracycline-based
chemotherapy [11–13] in ER-negative BC had already
been published. Accordingly, the use of FAC-T in patients
with ER-negative BC was also included into the St.Gallen
recommendations [39–43]. The most recent clinical prac-
tice guidelines of the National Comprehensive Cancer Net-
work (NCCN) do not recommend grading chemotherapy
according to the risk of disease recurrence, but usually in-
clude taxanes as the “preferred adjuvant regimens” [23].
In the present study, known pathological risk factors as
well as patient age ≤50 years were over-represented in pa-
tients receiving FAC-T compared to those receiving non-
FAC-T chemotherapy, and FAC-T chemotherapy was typ-
ically used in a risk-adapted manner in unselected patients
with BC, with tumour biology becoming more important to
choose FAC-T chemotherapy in ER-negative high-risk pa-
tients.
While the use of chemotherapy according to tumour risk
and biology is in accordance with treatment recommend-
ations, we found that socioeconomic and geographical
factors were also important for choosing the type of chemo-
therapy in some cases. Interestingly, regional variability
for using FAC-T or non-FAC-T chemotherapy was rather
substantial, and this was independent of the patient’s dis-
ease risk profile (unselected, ER-negative BC patients). At
present, the implementation of anti-HER2 targeted treat-
ment adds another level of complexity to modern breast
cancer care [44].
Schrijvers et al. reported the results of a study in 29’676
women in the UK with newly diagnosed BC [45]. Overall
survival from BC was inversely related to socioeconomic
deprivation, as determined by a residential district index
that included pre-specified items [45]. Similar results were
reported from a comparison of patients from affluent and
deprived areas of Scotland [46]. In Switzerland, similar re-
gional disparities in BC clinical outcome were reported,
despite the universal access to health care in Switzerland
[47], raising the question of whether heterogeneity in early
BC treatment may account for different clinical outcomes.
Table 2: Use of FAC-T chemotherapy in patient subgroups.
ER-positive (%) ER-negative (%)
477/1033 (46%) 300/496 (60)
N-positive (%) N-negative (%) N-positive (%) N-negative (%)
Subgroup Patients (%) 398/746 (53) 79/287 (28) 197/275 (72) 103/221 (47)
≤50 years 371/647 (57) 180/282 (64) 48/157 (31) 91/112 (81) 49/93 (53)
>50 years 410/888 (46) 218/464 (47) 31/130 (24) 106/163 (65) 54/128 (42)
G1 or G2 374/853 (44) 277/541 (51) 41/185 (22) 37/63 (59) 17/61 (28)
G3 382/642 (60) 107/190 (56) 35/96 (37) 153/198 (77) 86/158 (54)
Stage I to II 459/1,075 (43) 185/428 (43) 78/282 (28) 93/144 (65) 101/219 (46)
Stage III 322/460 (70) 213/318 (67) 1/5 (20) 104/131 (79) 2/2 (100)
ER = oestrogen receptor status, N = nodal status, G = histological grading.
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Unfortunately, there are very few data on the heterogeneity
of systemic treatment in early BC patients. In the subset
of 1,317 pre-menopausal ER-positive BC patients pooled
from the PERCHE and TEXT studies, geography was a
determinant of chemotherapy use [48]. The present study
suggests that in countries with good access to health care
services, there remain some imbalances in the prescribing
patterns of therapies such as the type of chemotherapy
used, and this may also have some impact on clinical out-
come.
The results of this study should be considered with respect
to the Swiss health care system, which is characterised by
mandatory health insurance, universal access to modern
health care services for all citizens, and by decentralisation
and high fragmentation. The Swiss health care system
shares several characteristics with the U.S. health care sys-
tem, even more so with the planned introduction of univer-
sal health care insurance in the U.S. In fact, similar studies
with regards to patient ethnicity were recently performed in
the U.S. by Griggs and colleagues [49]. In the latter study,
the authors found non-standard adjuvant chemotherapy re-
gimens in 112 out of 957 women (12%) treated for early
BC between March 2002 and March 2005, with African-
American women being almost twice as likely to receive
non-standard chemotherapy than non-African-American
women [49]. In the present study, 105 women out of 1535
women (7%) received non-registered chemotherapy drugs
for early BC, or chemotherapy that proved to be inferior
when tested against standard regimens, a proportion that
is somewhat lower than that found by Griggs and col-
leagues [49]. The strengths of the current study include the
prospective planning of data analysis, registry-based case
identification that enabled the authors to study patients in
the community setting, and avoidance of systemic bias in
patient accrual by central planning and structured patient
inclusion. Our study is limited by its retrospective nature,
missing data on the type of health care insurance, education
and surgical caseload, and the fact that menopausal status
had to be defined by using the age of 50 years as a cut off.
In the present study, missing data cannot be considered at
random, potentially resulting in some bias [50]. Our obser-
vations nevertheless are population-based and reflect clin-
ical practice in a community setting. By including all types
of providers, identification of patients through cancer re-
gistries, and achieving a large and very complete data set,
potential selection bias was substantially reduced. Finally,
clinical outcome data are not available at present, mainly
because the follow-up time is too short for most patients.
In conclusion, tumour biology is a predominant factor for
choosing FAC-T over older chemotherapy regimens in pa-
tients with ER-negative early BC, but improvements
should be made to reduce the substantial regional hetero-
geneity. Further epidemiological studies should assess how
the use of FAC-T chemotherapy is affecting clinical out-
come in patients with early BC and different risk profiles.
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Figures (large format)
Figure 1
Consort diagram.
* calculated from the breast cancer yearly average incidence rates in the periods 1999–2003 and 2004–2008 (http://www.nicer.org/Editor/files/
cancer_incidence.pdf)
BC = breast cancer, NSCT = nonstandard chemotherapy regimens.
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Figure 2
Forrest plot for the use of FAC-T chemotherapy compared to non-FAC-T chemotherapy in the overall study group (ER-positive and ER-negative
early breast cancer). Clinical significance (p <0.01) from adjusted multivariate analysis is marked by an asterisk. OR = odds ratio, ER =
oestrogen receptor, BC = breast cancer, MDTC = multidisciplinary tumour conference.
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Figure 3
Forrest plot for the use of FAC-T chemotherapy compared to non-FAC-T chemotherapy in patients with ER-negative early breast cancer. Clinical
significance (p <0.01) from adjusted multivariate analysis is marked by an asterisk. OR = odds ratio, BC = breast cancer, MDTC =
multidisciplinary tumour conference.
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